Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2017 in bone metastases from solid tumors
NCT07028268Phase 2Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jun 2025
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-2017 in bone metastases, sponsored by Suzhou Suncadia Biopharmaceutical. Started Jun 2025; status: recruiting.
02
Drugs
SHR-2017
03
Conditions
bone metastases
Beyond the preview
Go deeper on NCT07028268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07028268.